Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Linical Co., Ltd. ( (JP:2183) ) has shared an update.
Linical Co., Ltd. has revised its financial forecast for the fiscal year ending March 2026, citing lower-than-expected sales and profits due to a challenging business environment and delays in project acquisitions. Despite securing large-scale projects in Japan and advancing contracts in Europe and the U.S., the company anticipates revenue shortfalls. Additionally, Linical recorded a loss on income tax adjustments due to the non-recoverability of certain deferred tax assets, impacting its financial outlook.
The most recent analyst rating on (JP:2183) stock is a Hold with a Yen348.00 price target. To see the full list of analyst forecasts on Linical Co., Ltd. stock, see the JP:2183 Stock Forecast page.
More about Linical Co., Ltd.
Linical Co., Ltd. operates in the pharmaceutical industry, providing clinical trial services and collaborating with domestic and global pharmaceutical companies. The company focuses on large-scale projects and global clinical trials, with operations in Japan, Europe, the United States, and South Korea.
Average Trading Volume: 19,378
Technical Sentiment Signal: Sell
Current Market Cap: Yen7.91B
See more insights into 2183 stock on TipRanks’ Stock Analysis page.